| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Leukemia | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Leukemia, Myeloid | |||||
| Leukemia, Myeloid, Acute | |||||
| 3 | More general conditions related to this trial | ||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| 4 | Interventions listed in this trial | ||||
| recombinant flt3 ligand | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Flt3 ligand protein | |||||
| 6 | More general drug interventions related to this trial | ||||
| Adjuvants, Immunologic | |||||
| Immunologic Factors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Protective Agents | |||||
| Radiation-Protective Agents | |||||
| 7 | Sponsors listed in this trial | ||||
| Eastern Cooperative Oncology Group | |||||
| National Cancer Institute (NCI) | |||||
| Cancer and Leukemia Group B | |||||
| Southwest Oncology Group | |||||
|
